It has been observed that the administration of an anti-CD25 antibody to block Tregs prior to VEGF blockade therapy can restore the anti-tumor responsiveness mediated by anti-VEGFR2.[94] Therapeutic antibodies targeting CD25 have been utilized in clinical trials and have shown manageable levels of toxicity.[95] Given that CD25 serves as a receptor subunit for IL-2 and that inhibiting CD25 can disrupt IL-2 signaling in effector T cells, Solomon et al devised a new anti-CD25 antibody (RG6292) with the aim of preserving IL-2 levels. The gene discussed is IL2; the disease is neoplasm.